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Backgound
Chronic treatment with sodium nitrite has been shown to
be efficacious in preclinical models of pulmonary arterial
hypertension (PAH). The present study was designed to
test the acute hemodynamic effects and safety of inhaled
nitrite in patients with PAH (treatment naïve or on back-
ground therapy). Details: http://www.clinicaltrials.gov
NCT01431313 METHODS: Inhaled nitrite was delivered
at incremental doses (45 and 90 mg) to WHO group I
and WHO Group III PAH patients undergoing clinical
right heart catheterization for the diagnosis or manage-
ment of PAH. In addition to clinical measures of safety
and treatment response, novel hemodynamic parameters
of RV function were acquired by both micromanometry
and echocardiography.
Results
Inhaled nitrite was well tolerated by all subjects (n=10) at
both the 45mg and 90 doses in treatment naïve and
patients on background therapy (mean systemic blood
pressure and systemic vascular resistance were not altered
at either dose (NS; P>0.05) including patients on back-
ground PDE5A inhibitor therapy (n=8). Inhaled nitrite
lowered mean pulmonary arterial pressure (mPAP) and
pulmonary vascular resistance (PVR) in a dose-dependent
manner. Inhaled nitrite 45mg and 90 mg doses lowered
mPAP by 9.6+0.6% and 12.4+2.2 (P<0.0001) and PVR by
12.4+5.3% and 19.3+5.3% (P=0.006), respectively. Interest-
ingly, inhaled nitrite resulted in a marked lowering of right
atrial pressure (P<0.001) and pulmonary capillary wedge
pressure (P<0.001). When coupled with the observation of
improvements in dP/dtmin, these data suggest that inhaled
nitrite may exert a novel lusitropic ventricular effect.
Nitrite inhalation resulted in a significant increase in
plasma cGMP concentrations.
Conclusion
This preliminary analysis of an open-label study of
inhaled nitrite in patients with PAH provide evidence for
tolerability of the drug in treatment naïve and patients
on background therapy (including PDE5A inhibitors).
Moreover, these data demonstrate that inhaled nitrite
induces a dose-dependent reduction in mPAP and PVR
in patients with PAH.
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